# NEWAMSTERDAM PHARMA COMPANY (NAMSW)

> Institutional ownership reported to the SEC as of Q2 2026, from Form 13F filings. Source: https://holderbook.com/stocks/NAMSW/

- Reporting holders: 10
- Reported value: $29.7M
- Shares held by institutions: 1,309,194 of 119,537,169 outstanding
- Held through calls: 5.4%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Frazier Life Sciences Management, L.P.](https://holderbook.com/funds/1892134-frazier-life-sciences-management-l-p/) | $10.7M | 500,333 | 0.2% | 15 |
| [RA CAPITAL MANAGEMENT, L.P.](https://holderbook.com/funds/1346824-ra-capital-management-l-p/) | $7.1M | 333,333 | 0.1% | 15 |
| [Affinity Asset Advisors, LLC](https://holderbook.com/funds/1773195-affinity-asset-advisors-llc/) | $5.3M | 245,000 | 0.2% | 14 |
| [Bain Capital Life Sciences Investors, LLC](https://holderbook.com/funds/1703031-bain-capital-life-sciences-investors-llc/) | $2.1M | 99,999 | 0.1% | 15 |
| [DEERFIELD MANAGEMENT COMPANY, L.P.](https://holderbook.com/funds/1009258-deerfield-management-company-l-p/) | $2.0M | 92,787 | 0.0% | 15 |
| [MILLENNIUM MANAGEMENT LLC](https://holderbook.com/funds/1273087-millennium-management-llc/) | $1.6M | 0 | 0.0% | 15 |
| [ARISTEIA CAPITAL, L.L.C.](https://holderbook.com/funds/1080171-aristeia-capital-l-l-c/) | $343.4K | 15,708 | 0.0% | 3 |
| [WOLVERINE ASSET MANAGEMENT LLC](https://holderbook.com/funds/1279891-wolverine-asset-management-llc/) | $318.9K | 14,925 | 0.0% | 2 |
| [Vestcor Inc](https://holderbook.com/funds/1536925-vestcor-inc/) | $143.0K | 6,666 | 0.0% | 15 |
| [UBS Group AG](https://holderbook.com/funds/1610520-ubs-group-ag/) | $8.5K | 443 | 0.0% | 7 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q2 2026 | 10 | $29.7M |
| Q1 2026 | 10 | $27.5M |
| Q4 2025 | 10 | $31.6M |
| Q3 2025 | 10 | $23.5M |
| Q2 2025 | 11 | $11.0M |
| Q1 2025 | 11 | $13.0M |
| Q4 2024 | 12 | $19.8M |
| Q3 2024 | 12 | $9.8M |
| Q2 2024 | 11 | $12.1M |
| Q1 2024 | 12 | $16.7M |
| Q4 2023 | 19 | $5.9M |
| Q3 2023 | 20 | $3.6M |